Anika Therapeutics (ANIK) Retained Earnings (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Retained Earnings data on file, last reported at $55.7 million in Q1 2026.

• Retained Earnings for Q1 2026 came in at $55.7 million, down 16.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.7 million (down 16.56% YoY), and the FY2025 annual result was $60.8 million, down 15.18% from the prior year.
• Retained Earnings declined to $55.7 million in Q1 2026 per ANIK's latest filing, from $60.8 million in the prior quarter.
• Over five years, Retained Earnings peaked at $222.6 million in Q1 2022 and troughed at -$6.6 million in Q3 2023.
• A 5-year average of $88.9 million and a median of $66.8 million in 2025 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 4630.13% in 2022, then tumbled 105.28% in 2025.
• A 5-year view of Retained Earnings shows it stood at $210.7 million in 2022, then sank by 39.23% to $128.1 million in 2023, then sank by 44.03% to $71.7 million in 2024, then slipped by 15.18% to $60.8 million in 2025, then dropped by 8.32% to $55.7 million in 2026.
• Business Quant data shows ANIK's Retained Earnings at $55.7 million in Q1 2026, $60.8 million in Q4 2025, and -$4.9 million in Q3 2025.